Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 26 Nov 2025 | Ann-Sofie Ronnlund Cabinet member | Life sciences | SRC |
| 26 Nov 2025 | Ekaterina Zaharieva Commissioner | Life sciences | SRC |
| 26 Nov 2025 | Ekaterina Zaharieva Commissioner | Life sciences | — |
| 08 Jul 2025 | Vilija Sysaite Cabinet member | Biotech | SRC |
| 08 Jul 2025 | Vilija Sysaite Cabinet member | Biotech | — |
| 10 Jun 2025 | Laszlo Andrejko Cabinet member | Preparation for the upcoming Biotech Act | — |
| 10 Jun 2025 | Laszlo Andrejko Cabinet member | Preparation for the upcoming Biotech Act | SRC |
| 19 Sept 2023 | Karolina Herbout-Borczak Cabinet member | Exchange of views with the Alliance for Regenerative Medicine on the implementation of the HTA Regulation as well as the reform of the EU Pharmaceutical Legislation. | — |
| 19 Sept 2023 | Karolina Herbout-Borczak Cabinet member | Exchange of views with the Alliance for Regenerative Medicine on the implementation of the HTA Regulation as well as the reform of the EU Pharmaceutical Legislation. | SRC |
| 27 Jan 2022 | Karolina Herbout-Borczak Cabinet member | Exchanges of views on policy priorities of the Alliance for Regenerative Medicine in Europe: the Pharmaceutical Strategy and the EU’s Beating Cancer Plan | SRC |
| 27 Jan 2022 | Karolina Herbout-Borczak Cabinet member | Exchanges of views on policy priorities of the Alliance for Regenerative Medicine in Europe: the Pharmaceutical Strategy and the EU’s Beating Cancer Plan | — |
| 08 Nov 2017 | Annika Nowak Cabinet member | Advanced therapy medicinal products | — |
| 08 Nov 2017 | Annika Nowak Cabinet member | Advanced therapy medicinal products | SRC |
Mission & Goals
The Alliance for Regenerative Medicine (ARM, www.alliancecerm.org) is the international advocacy organization dedicated to realizing the promise of advanced therapy medicinal products (ATMPs). ARM promotes legislative, regulatory, reimbursement and manufacturing initiatives in Europe and globally to advance this innovative and transformative sector, which includes cell and gene therapies, and tissue-based therapies. ARM is the global voice of the sector, representing 400+ members worldwide, including SMEs, large companies, academic research institutions, major medical centres and patient groups.
EU Legislative Interests
ARM is interested in following any legislative or policy initiative on advanced therapies, including on broader aspects which may have an impact on advanced therapies such as initiatives on pharmaceuticals, blood, tissues and cells, clinical trials, orphan medicines, health technology assessment, health data, cross-border healthcare. ARM is also interested in initiatives and policy developments relating to small and medium size enterprises and access to capital.
Communication Activities
As part of its activities, ARM releases policy recommendations, policy papers and reports. ARM produces regular reports providing an overview of the sector including data on clinical trial, therapeutic developers and investment in the sector. ARM also publishes a newsletter for its members where regulatory, legislative and policy developments in Europe and elsewhere are reported. ARM organizes an annual meeting on advanced therapies in Europe, named the Cell & Gene Meeting on the Mediterranean. See more on www.alliancerm.org
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Standards Coordinating Body for Gene, Cell and Regenerative Medicines and Cell-Based Drug Discovery Foundation for Cell and Gene Medicine National Academy of Sciences Forum on Regenerative Medicine
Organisation Members
ARM members are over 400 and include public and private companies (the majority of which are small- and medium-size enterprises), research institutions, investors, patient advocates/foundations and associations, affiliate members. See list on https://alliancerm.org/members/members-and-profiles/